Company press releases and official corporate announcements.
A centralized feed of corporate press releases, earnings announcements, mergers, and official statements. Content is presented for informational purposes and may require additional analysis for market relevance.
24,445 total articles
Climb Global Solutions, Inc., a U.S.-based technology distributor, announced a distribution partnership with Harmonic Security to offer its AI governance platform to value-added resellers and managed service providers. This collaboration targets enhanced security for mid-market and enterprise adoption of AI, addressing risks from autonomous AI agen…
VisionWave Holdings, Inc. announced a planned acquisition of at least 51% of D-Fence Electronic Fencing Systems Ltd., an Israeli developer of AI-driven perimeter security technologies used in critical infrastructure worldwide. The transaction aims to build a comprehensive AI-powered defense platform by integrating D-Fence's solutions with VisionWav…
NewAmsterdam Pharma reported positive regulatory milestones, including a favorable CHMP opinion recommending marketing authorization for obicetrapib and its fixed-dose combination with ezetimibe in Europe. The company provided updates on ongoing Phase 3 cardiovascular and Alzheimer's disease trials, announced cash position of $678.3 million as of J…
BioCryst Pharmaceuticals reported robust Q2 2026 financial results with total net revenue of $218.3 million, an operating profit of $98.5 million, and maintained full-year ORLADEYO revenue guidance while raising total revenue outlook. Key milestones include starting shipments of ORLADEYO oral pellets for pediatric hereditary angioedema patients and…
Ascent Solar Technologies highlights its growing involvement in the expanding drone market alongside its core space industry applications. The company secured orders from satellite manufacturers and unmanned aerial and marine vehicle producers, showcasing its innovative thin-film photovoltaic technology that offers a superior power-to-weight ratio.…
Kymera Therapeutics reported Q2 2026 financial results highlighting rapid enrollment completion of their KT-621 Phase 2b trial in atopic dermatitis ahead of schedule, with topline data expected by year-end 2026. The company plans to initiate Phase 3 trials in mid-2027 and reported ongoing progress in multiple clinical programs addressing immunologi…
Sprott Inc. announced its Q2 2026 results with Assets Under Management (AUM) declining 15% from Q1 due to corrections in gold and silver prices. Despite this, average AUM grew 70% year over year, driven by strong inflows and market appreciation in critical materials products. Management fees increased by 72% year over year, while net income rose to…
Geron Corporation reported an 11% increase in net product revenue for its RYTELO (imetelstat) drug in Q2 2026 compared to Q1, reaching $57.5 million. The company reaffirmed its 2026 financial guidance, expecting RYTELO net product revenues between $220 million and $240 million. Geron expanded its leadership team, presented positive real-world effic…
Factorial Energy Inc., a US-based innovator in solid-state battery technology, announced its plans to attend the Oppenheimer Technology, Internet & Communications Conference and the J.P. Morgan Auto Conference in August 2026. The company highlighted its proprietary battery platforms backed by prominent industry and strategic investors and recent pe…
Entrada Therapeutics reported its second quarter 2026 financial results, highlighting strong progression in its clinical pipeline targeting neuromuscular diseases like Duchenne muscular dystrophy (DMD) and myotonic dystrophy type 1 (DM1). Key clinical data readouts for their ENTR-601 program cohorts are expected between late 2026 and early 2027, al…
Seres Therapeutics announced second quarter 2026 financial results highlighting a net income of $4.6 million, driven by a $25 million milestone payment from Nestlé for the VOWST business sale. The company reported encouraging investigator-sponsored trial results for SER-155 in immune checkpoint inhibitor-related enterocolitis (irEC), showing 80% of…
Rapport Therapeutics reported Q2 2026 financial results and business updates, highlighting the initiation of two Phase 3 trials (FOCUS 1 and FOCUS 2) for RAP-219 in focal onset seizures. The company remains on track for topline Phase 2 results in bipolar mania later in 2026 and is progressing other pipeline candidates including a long-acting inject…
Tonix Pharmaceuticals, a commercial-stage biotech company focusing on CNS disorders, infectious diseases, immunology, and rare diseases, announced their upcoming participation in two investor conferences. Leadership will present company progress and pipeline developments, including marketed products TONMYA® for fibromyalgia and acute migraine treat…
Kamada Ltd., a global biopharmaceutical company specializing in specialty plasma-derived therapies and treatment for rare and serious conditions, announced it will release its second quarter and first half 2026 financial results on August 12, 2026, before U.S. markets open. The company will host a conference call to discuss results and provide upda…
GLOBALFOUNDRIES Inc. announced its preliminary Q2 2026 financial results, reporting revenue of $1.786 billion, surpassing guidance. The company demonstrated strong margin expansion and net income, driven by growing demand in AI data center solutions, semiconductor technology innovation, and strategic acquisitions. GF secured a $300 million governme…
Orion Energy Systems, Inc. reported a strong first quarter for fiscal 2027, with revenue increasing 32% year-over-year to $25.7 million, driven by growth across LED lighting, EV charging, and maintenance services. The company returned to profitability, achieving net income of $2 million and its seventh consecutive quarter of positive adjusted EBITD…
EyePoint, Inc. reports Q2 2026 financial results highlighting progress in its DURAVYU pivotal Phase 3 trials for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). Topline data for wet AMD trials LUGANO and LUCIA are expected in August 2026 and Q4 2026 respectively, while pivotal DME trials COMO and CAPRI are fully enr…
The Brink's Company announced solid second-quarter 2026 results, highlighting 7% revenue growth driven by continued mid-teens organic growth in their AMS and DRS businesses. Net income rose 2%, while adjusted EBITDA increased 11%, and non-GAAP EPS grew 18%. The company reported record operating profit margins and free cash flow improvements. Regula…
AC Immune SA provided a first half 2026 update highlighting clinical advances in its wholly-owned programs targeting neurodegenerative diseases, notably Parkinson's and Alzheimer's. The Phase 2 trial of ACI-7104 in Parkinson’s disease progresses with full results expected in H2 2026, supported by a $4 million grant. The Alzheimer’s focused ACI-24 t…
Shopify announced strong financial results for Q2 2026, achieving a 34% year-over-year revenue increase, 30%+ growth in gross merchandise volume (GMV), gross profit, and free cash flow with margins reaching 18%. The company demonstrated broad-based growth across all merchant sizes and geographies, driven by the integration of AI and increased opera…
Crown Crafts, Inc., a US-based producer and distributor of infant and juvenile consumer products, will report its Q1 fiscal 2027 financial results on August 12, 2026, followed by a teleconference hosted by company executives. The company designs and markets a variety of infant and toddler products through its subsidiaries and sells to multiple reta…
Flutter Entertainment announced its Q2 2026 financial results with 3% revenue growth driven by international markets and iGaming but reported a net loss of $296 million, significantly down from prior year profit. US revenue declined 6% led by sportsbook declines offset by strong iGaming growth. Adjusted EBITDA fell 45% overall, with US adjusted EBI…
Natural Resource Partners L.P. (NYSE: NRP) reported solid second quarter 2026 financial results, generating $41.7 million in free cash flow and declaring a $0.75 distribution per common unit for Q2. The company highlights progress toward debt repayment and plans to increase distributions by year-end. While mineral rights revenues improved due to hi…
Flutter Entertainment plc announced that Dan Taylor will succeed Peter Jackson as Group CEO, effective October 1, 2026. Taylor currently leads Flutter's International division, contributing significantly to the group's revenue and EBITDA, and has played a crucial role in recent strategic acquisitions and FanDuel sportsbook improvements. The transit…
Eton Pharmaceuticals has acquired the U.S. rights to ASN-001, a late-stage topical product candidate targeting moderate infantile hemangiomas, complementing their existing oral treatment HEMANGEOL. ASN-001 showed promising Phase II/III results with significantly higher elimination rates compared to placebo and is expected to reach FDA submission by…
